These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 17139593

  • 1. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [Abstract] [Full Text] [Related]

  • 2. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D.
    Clin Chest Med; 2007 Mar 08; 28(1):117-25, viii. PubMed ID: 17338931
    [Abstract] [Full Text] [Related]

  • 3. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.
    Can J Cardiol; 2013 Jun 08; 29(6):672-7. PubMed ID: 22819360
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G.
    Dtsch Med Wochenschr; 2008 Oct 08; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P, Amoura Z, Langleben D.
    Rev Med Interne; 2008 Apr 08; 29(4):283-9. PubMed ID: 18243424
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Apr 08; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ.
    J Heart Lung Transplant; 2007 Jan 08; 26(1):63-9. PubMed ID: 17234519
    [Abstract] [Full Text] [Related]

  • 14. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA.
    IDrugs; 2009 Jun 08; 12(6):366-75. PubMed ID: 19517317
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M, Porter S, Granton J.
    Drug Saf; 2015 May 08; 38(5):419-35. PubMed ID: 25792028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, STRIDE-2 Study Group.
    J Am Coll Cardiol; 2006 May 16; 47(10):2049-56. PubMed ID: 16697324
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.